Medigene AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 86
- Market Cap
- $33.8M
- Website
- http://www.medigene.de
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
Phase 1
Not yet recruiting
- Conditions
- Epithelial Ovarian CancerGastro-esophageal Junction CancerSoft Tissue Sarcoma (STS)Myxoid LiposarcomaSynovial Sarcoma
- Interventions
- Drug: LymphodepletionBiological: TCR-T cells (MDG1015)
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Medigene AG
- Target Recruit Count
- 55
- Registration Number
- NCT06748872
- Locations
- πΊπΈ
Fred Hutch Cancer Center, Seattle, Washington, United States
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Phase 1
Withdrawn
- Conditions
- Acute Lymphoid LeukemiaMyeloproliferative DisordersAcute Myeloid LeukemiaMyelofibrosisMultiple MyelomaMyelodysplastic SyndromesChronic Myeloid LeukemiaMalignant Lymphoma
- Interventions
- Drug: MDG1021 dose 1Drug: MDG1021 dose 2Drug: MDG1021 dose 3Drug: MDG1021 optimal dose
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Medigene AG
- Registration Number
- NCT04464889
- Locations
- π³π±
Leiden University Medical Centre, Leiden, Zuid Holland, Netherlands
TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms
Phase 1
Terminated
- Conditions
- SafetyTolerabilityFeasibilityTreatment Efficacy
- Interventions
- Drug: MDG1011Other: Investigator Choice therapy
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Medigene AG
- Target Recruit Count
- 9
- Registration Number
- NCT03503968
- Locations
- π©πͺ
University Hospital Erlangen, Erlangen, Germany
π©πͺUniversity Hospital Freiburg, Freiburg, Germany
π©πͺUniversity Hospital Mainz, Mainz, Germany
DC Vaccination for Post-remission Therapy in AML
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: WT1/PRAME vaccination
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Medigene AG
- Target Recruit Count
- 20
- Registration Number
- NCT02405338
- Locations
- π³π΄
Oslo University Hospital, Rikshospitalet, Oslo, Norway
Β© Copyright 2025. All Rights Reserved by MedPath